STOCK TITAN

HAEMONETICS (HAE) SEC Filings

HAE NYSE

Haemonetics Corporation filings document current-report disclosures for a Massachusetts medical technology company focused on hospital, plasma collection and blood center products. Recent Form 8-K filings cover quarterly and annual operating results, furnished earnings releases, and Regulation FD disclosures related to corporate responsibility reporting and capital-structure events.

The company’s filings also record governance and board matters, including director and committee disclosures tied to annual meeting processes. Material-event reports document financing and corporate actions such as repayment of convertible senior notes and the completed acquisition of Vivasure Medical Limited, a percutaneous vessel closure technology company.

Rhea-AI Summary

Haemonetics Corp. (HAE) VP, Chief Accounting Officer Farris Maryanne Maunsell exercised options for 1,068 shares at $89.16, 645 shares at $95.73, and 433 shares at $70.31 on November 11, 2026, acquiring the corresponding common shares. She also delivered or had withheld 1,724 shares for payment of exercise price or tax liability, and sold 836 shares at a weighted average price of $120.99 in multiple transactions ranging from $120.87 to $121.10. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.30%
Tags
insider
-
Rhea-AI Summary

Haemonetics Corp officer Maryanne Farris reported a proposed sale of 836 common shares, with an aggregate market value of $101,144.38 and an approximate sale date of November 11, 2026. The securities table lists three restricted-stock vesting acquisitions and one stock option exercise among the acquisition transactions for securities identified for sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.80%
Tags
other
-
Rhea-AI Summary

Haemonetics Corporation (HAE) reported net revenue of $357.8 million for the three months ended September 26, 2026, up 9.3% from $327.3 million a year earlier. Operating income was $75.1 million, up 28.4%, and net income was $46.3 million, up 19.7%; diluted earnings per share were $1.00 versus $0.81. The company attributed revenue gains mainly to volume growth and share gains in Apheresis Plasma, and share gains in MedSurg’s Hemostasis Management and Transfusion Management product lines.

For the six months ended September 26, 2026, net revenue was $697.1 million and operating cash flow was $180.4 million. Cash and cash equivalents were $260.7 million, with $200.0 million outstanding under the revolving credit facility as of September 26, 2026. Haemonetics acquired Vivasure Medical Limited for a net purchase price of $166.0 million on January 9, 2026; the FDA approved Vivasure’s PerQseal Elite for large-bore arterial procedures in October 2026, and Haemonetics will conduct and report periodically to the FDA on a post-approval study. A non-exclusive supply agreement with CSL Plasma has no minimum purchase commitments; CSL expects rollout completion by the end of calendar year 2027, with scope and timing subject to change.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.60%
Tags
quarterly report
Rhea-AI Summary

Haemonetics Corporation (HAE) reported second-quarter fiscal 2027 revenue of $357.8 million, up 9.3% year over year, with organic revenue growth of 10.0%. GAAP net income rose 19.7% to $46.3 million, and diluted earnings per share increased 23.5% to $1.00. Apheresis revenue was $204.8 million, up 12.6%, while MedSurg revenue was $153.0 million, up 5.1%. GAAP operating margin was 21.0%, compared with 17.9% a year earlier.

Operating cash flow was $128.1 million, up $16.8 million, and free cash flow was $103.8 million, up $15.1 million. Adjusted earnings per diluted share were $1.35, up 6.3%; adjusted operating margin was 26.3%, down 40 basis points. Fiscal 2027 reported-revenue guidance is now 8–11%, versus 5–8% previously, and organic-revenue guidance is 6–9%, versus 4–7%. Adjusted operating-margin expansion guidance is 0–50 basis points, down from 50–100 basis points; free cash flow conversion guidance is >80%, compared with approximately 80% previously.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.60%
Tags
current report
-
Rhea-AI Summary

Haemonetics Corp. EVP, Chief Commercial Officer Roy Galvin had 146 shares withheld for tax obligations in connection with the vesting of previously reported restricted stock units on October 30, 2026. The reported price was $119.65 per share. His direct holdings following the transaction were 39,805 shares; that figure includes unvested RSUs and 69 shares acquired on October 31, 2026, under the Haemonetics Corporation 2007 Employee Stock Purchase Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
insider
-
Rhea-AI Summary

Haemonetics Corporation (HAE) updated investors on its non-exclusive supply agreement with CSL Plasma. CSL may use Haemonetics’ NexSys PCS® devices with Persona® PLUS technology and purchase related disposables in the United States. CSL expects to complete the rollout by the end of calendar year 2027 and currently anticipates a transition at all of its current U.S. plasma collection centers.

The rollout’s scope and timing remain subject to change under the agreement, and Haemonetics and CSL are still determining implementation details. Haemonetics is not updating its previously issued fiscal 2027 guidance at this time; it expects to provide an update on the agreement’s anticipated impact on fiscal 2027 results with its second fiscal quarter earnings call in November 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.46%
Tags
current report
Rhea-AI Summary

Haemonetics Corporation entered into a non-exclusive supply agreement with CSL Plasma Inc. under which CSL may use Haemonetics’ NexSys PCS® devices with Persona® PLUS technology and purchase related disposables for U.S. plasma collection centers. The agreement does not include minimum purchase commitments, and Haemonetics currently expects CSL to transition only a portion of its U.S. centers, with the scope and timing of that transition still undetermined. Because of this uncertainty, Haemonetics is not revising its fiscal 2027 guidance at this time and plans to discuss the anticipated financial impact of the agreement in conjunction with its second fiscal quarter earnings call in November 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.93%
Tags
current report
-
Rhea-AI Summary

AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC reported beneficial ownership of 2,266,489 shares of Haemonetics Corp common stock, representing 4.99% of the class as of 06/30/2026. Both entities report shared voting power over 2,149,735 shares and shared dispositive power over 2,266,489 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
ownership
-
Rhea-AI Summary

Haemonetics Corporation reported first-quarter fiscal 2027 net revenues of 339,380 (Dollars in Thousands), up 5.6% compared with the same period a year earlier. Operating income rose 6.7% to 57,458, while net income declined 3.0% to 33,010 and diluted EPS increased 2.9% to $0.72.

Apheresis net revenues grew 5.3%, led by volume growth and share gains in Plasma, and MedSurg revenues increased 6.0% on strength in Vascular Closure and Hemostasis Management. Gross margin remained 59.8%, supported by a shift toward higher-margin offerings and the absence of prior-year inventory fair value step-up amortization.

Net cash provided by operating activities improved to 52,323 from 17,395 (Dollars in Thousands). Cash and cash equivalents were 223,384 against total debt of 1,174,158. During fiscal 2026, the company repurchased 3,009,834 shares for $175.0 million under its 2025 program, leaving $325.0 million authorized as of June 27, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.70%
Tags
quarterly report
Rhea-AI Summary

Haemonetics reported first quarter fiscal 2027 revenue of $339.4 million, up 5.6% year over year with 5.9% organic growth. Apheresis revenue was $191.3 million and MedSurg revenue $148.1 million, both growing mid‑single digits, led by Plasma and Blood Management Technologies, while Interventional Technologies also returned to growth.

GAAP gross margin held at 59.8%. Operating income was $57.5 million with a 16.9% margin. Net income was $33.0 million and earnings per diluted share $0.72, slightly above $0.70 a year earlier despite a higher tax rate of 30.6%. Adjusted EPS was $1.14 on a 23.4% adjusted operating margin.

Cash flow from operating activities rose to $52.3 million and free cash flow to $39.1 million, supporting a cash balance of $223.4 million. Management raised fiscal 2027 guidance to 5–8% reported revenue growth and 4–7% organic growth, with 50–100 basis points of adjusted operating margin expansion and free cash flow conversion of about 80%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.70%
Tags
current report

FAQ

How many HAEMONETICS (HAE) SEC filings are available on StockTitan?

StockTitan tracks 64 SEC filings for HAEMONETICS (HAE), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for HAEMONETICS (HAE)?

The most recent SEC filing for HAEMONETICS (HAE) was filed on November 13, 2026.